Ranking Member Richard Neal, joined by Democratic leaders from the Energy and Commerce, Education and Workforce, and Senate Finance Committees, sent letters to four major pharmaceutical companies demanding details on their recent pricing agreements with the Trump administration. The lawmakers questioned whether the deals would lower drug costs or primarily benefit the Trump family and administration.
The letters request information on the structure and impact of the agreements, including effects on Medicare pricing, the scope of the TrumpRx platform, and any benefits received by the companies. The lawmakers argue that the administration has failed to provide evidence that the deals will result in consumer savings and allege that prior announcements have raised prices or lacked follow-through.
The press release frames the agreements as opaque and potentially self-serving, citing skepticism from economists and a lack of public documentation. The pharmaceutical companies were given until January 5, 2026, to respond to the committee’s inquiries.